Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Research-Evidence-Practice Gaps in Post-stroke Neuro-recovery Pharmacological Therapies in Asia.

Chiu HC, Yangchen Y, Pengiran Tengah DSNA, Chum NN, Lin Y, Fong WC, Pamidimukkala V, Pandian JD, Tjandrawidjaja G, Uchiyama S, Oh MS, Keosodsay S and 14 more

Show all authors

Tan KS, Ravdan A, Lay PP, Thapa L, Siddiqui M, Navarro JC, Chang HM, Ranawaka UK, Lee TH, Chan L, Roongpiboonsopit D, Suwanwela NC, Nguyen TH, Venketasubramanian N

Cerebrovascular diseases extra29 Jul 2026

PMID42525569 (opens in a new tab)DOI10.1159/000553635 (opens in a new tab)PepBankPUB-42525569
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneObservational studyOther

    In the Asian survey, edaravone, MLC601/MLC901, cerebrolysin and panax notoginseng were each reported available in about a third to half of surveyed countries or regions.

    In plain wordsIn the Asian survey, edaravone, MLC601/MLC901, cerebrolysin and panax notoginseng were available in about a third to half of surveyed countries or regions.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableAvailability across Asian countries or regions
    Study

    n: not reported in source

    Outcome group
    Patterns of use · Whole body

    Source sentences

    Summary
    Edaravone, MLC601/ MLC901, cerebrolysin and panax notoginseng are available in about a third to half of the countries or regions surveyed, while cinepazide and clomethiazole are generally unavailable.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.